linjc16/ctgov huggingface dataset:
Correlation of Biochemical Indexes and Retinal Hemodynamic in Patients With Different Degrees of Diabetic Retinopathy

Study Overview
=================
Brief Summary
-----------------
All OCTA data and biochemical indexes of diabetic patients were acquired. A prediction model of diabetic retinopathy was built, and the random forest method was used to identify sensitive indicators.

Detailed Description
-----------------
Diabetic patients at the Department of Ophthalmology of the Seventh Affiliated Hospital of Sun Yat-sen University were selected as research participants. All OCTA data and biochemical indexes were acquired. A prediction model of diabetic retinopathy was built, and the random forest method was used to identify sensitive indicators.

Official Title
-----------------
Correlation of Biochemical Indexes and Retinal Hemodynamic in Patients With Different Degrees of Diabetic Retinopathy

Conditions
-----------------
Diabetic Retinopathy

Intervention / Treatment
-----------------
* Diagnostic Test: imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of diabetes Exclusion Criteria: various other types of retinal and choroidal disease; history of any intraocular surgery or treatment (including intravitreal injection, retinal photocoagulation etc. with severe refractive medium opacity that could affect fundus examination.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>diabetic patients with no diabetic retinopathy | Diagnostic Test: imaging<br>* imaging<br>|
| Group 2<br>diabetic patients with mild nonproliferative diabetic retinopathy | Diagnostic Test: imaging<br>* imaging<br>|
| Group 3<br>diabetic patients with moderate and severe nonproliferative diabetic retinopathy | Diagnostic Test: imaging<br>* imaging<br>|
| Group 4<br>diabetic patients with proliferative diabetic retinopathy | Diagnostic Test: imaging<br>* imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting blood glucose (FBG) | biochemical indexes | the time of the patient's first 1 day visit | 
| glycosylated hemoglobin (HbAlc) | biochemical indexes | the time of the patient's first 1 day visit | 
| OCTA data | An image of the 3mm×3mm and 6 mm×6 mm macular areas detected by OCTA were captured. Quantitative analysis of vascular density and perfusion density of superficial capillary plexus in the macular area were automatically calculated using built-in software on the device. | the time of the patient's first 1 day visit |
Effect of Eyelid Patching After Ptosis Surgery

Study Overview
=================
Brief Summary
-----------------
The goal of this randomized, controlled, observer-blinded study is to compare the effect of compression dressing after ptosis surgery. The main question it aims to answer are: Effect of dressing on edema, hematoma, scar formation, ocular surface irritation and postoperative pain. Patients are randomized after surgery for compression dressing or not. Results are scored by a blinded observer. type of study: clinical trial

Official Title
-----------------
The Effect of Eyelid Patching After Anterior Lector Reinsertion and Blepharoplasty on Edema, Hematoma, Scar Formation and Ocular Surface Irritation

Conditions
-----------------
Ptosis, Eyelid

Intervention / Treatment
-----------------
* Other: Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ptosis Exclusion Criteria: kongenital ptosis, pre-surgery, trauma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: randomized for compression dressing or none
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Compression dressing<br>Randomized, eyes were patched with a compression dressing after surgery. | Other: Compression dressing (build by Kompressen, gauze swabs, Nobamed Paul Danz AG, Wetter, Germany and NOBALUMENAL® - steril, eye pad, Nobamed Paul Danz AG, Wetter, Germany<br>* Compression dressing after ptosis surgery<br>|
| No Intervention: No Compression dressing<br>Randomized, eyes were not patched with a dressing. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hematoma | degree of hematoma postoperatively. Ranked by a blinded observer on a four point rating scale (0=none, 1=mild, 2=moderate, 3=severe) using phtographies of the patients eyes. | First postoperative day until 8 weeks after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ptosis, Blepharoplasty, Eyelid surgery
Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.

Official Title
-----------------
Verification of Prognostic Risk Factors of Thrombohemorrhagic Complications in Early Follow-up Period in Recipients After Living Related Liver Transplantation

Conditions
-----------------
Liver Cirrhosis, Liver Transplant; Complications

Intervention / Treatment
-----------------
* Procedure: Liver transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years and up to 70 years; Signed informed consent for inclusion to the study; End stage liver cirrhosis. Exclusion Criteria: Pregnancy; Extrahepatic factors influencing systemic hemostasis; Concomitant hematological diseases affecting the hemostatic system; Severe concomitant disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| liver transplant group<br> | Procedure: Liver transplantation<br>* Related transplantation of the right lobe of the liver<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombosis of vascular anastomosis | Thrombosis of arterial or venous anastomosis after intervention | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemorrhagic complications | Any hemorrhagic complications after intervention | 1 month |
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Study Overview
=================
Brief Summary
-----------------
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. Development of related AEs Contributing factors possibly having an impact on the safety and effectiveness Development of unexpected related AEs

Detailed Description
-----------------
The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. Development of related AEs Contributing factors possibly having an impact on the safety and effectiveness Development of unexpected related AEs This investigation will be conducted to support the application for re-examination specified in Article 14-4 of the Act on Securing Quality, Effectiveness and Safety of Products Including Pharmaceuticals and Medical Devices.

Official Title
-----------------
TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients With Bronchial Asthma.

Conditions
-----------------
Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The evaluable patients are those treated with Tezspire for the first time due to Bronchial asthma (only the patients with severe or intractable bronchial asthma which could not be controlled with the existing therapy) Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ADRs | the incidence of ADRs related to Tezspire Safety Specifications: Serious hypersensitivity, infection, malignancy, cardiac disorders | 156 weeks |
Validity and Reliability of the Turkish St. Marks Incontinence Score

Study Overview
=================
Brief Summary
-----------------
For the Turkish validity and reliability study of St.Mark's (Vaizey) Incontinence Score, which consists of 7 questions, it will be applied to 65 people diagnosed with anal incontinence after it is translated by translation-retranslation method.

Official Title
-----------------
Validity and Reliability of the Turkish St. Marks Incontinence Score

Conditions
-----------------
Fecal Incontinence, Pelvic Floor Disorders

Intervention / Treatment
-----------------
* Other: Anal incontinence patients with St. Mark's Incontinence Score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: people with the complatint of anal incontinence being volunteered to participate Exclusion Criteria: - having difficulties in understanding and speaking Turkish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Anal incontinence patients with St. Mark's Incontinence Score|The scale was applied to the patients who applied to our clinic with the diagnosis of anal incontinence.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turkish Validation and Reliability of St. Mark's Incontinence Score | St. Mark's Incontinence Score which shows the disease severity of anal incontinence patients and is used in the follow-up of their recovery status. The Turkish validity and reliability study of Mark's incontinence score will be conducted and it will be translated into Turkish. | 1 month |
Comparison of Kinesio Tape and Dry Needling for the Management of Rotator Cuff Tendinopathy: A Randomized Control Trial

Study Overview
=================
Brief Summary
-----------------
Its a single blind RCT

Detailed Description
-----------------
Kinesio tape and dry needling were compared for the management of rotator cuff tendinopathy

Official Title
-----------------
Comparison of Kinesio Tape and Dry Needling for the Management of Rotator Cuff Tendinopathy: A Randomized Control Trial

Conditions
-----------------
Rotator Cuff Tendinopathy

Intervention / Treatment
-----------------
* Other: kinesio tape
* Other: Dry needling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 25-50 years old Both genders Not any comorbidity Exclusion Criteria: Parkinson disease DM HTN

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Single blind RCT
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A<br>. Group A was given kinesio tape.Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient | Other: kinesio tape<br>* kinesio tape was applied over the specific muscle of rotator cuff<br>|
| Active Comparator: Group B<br>. Group A was given dry needling. Total six sessions of each intervention were given to each patient at a rate of two sessions per week along with the 10 minutes of interferential therapy and 10 minutes of moist packs to each patient | Other: Dry needling<br>* dry needling was applied over the affected muscles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PNS | Pain numeric Scale consists of 10 scores. 0 means no pain and 10 means worst pain ever | will be used to assess at baseline after 3 weeks | 
| SF-36 | short form 36 is used to measure the quality of life. lower scores means lower quality of life and ligher score means better quality of life | will be used to assess at baseline after 3 weeks |
A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.

Official Title
-----------------
International Real-World Study of MET Overexpression in Patients With Non-Small Cell Lung Cancer

Conditions
-----------------
Non Small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously consented and/or prospective collection of consent for research use of banked biological materials and clinical data. Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer (NSCLC). Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019. Exclusion Criteria: Specimens collected before 2019. Insufficient specimen tissue for testing. Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing. Adenosquamous and sarcomatous histologies of NSCLC.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants Undergoing Chart Review<br>Participants treated for non small cell lung cancer undergoing chart review and retrospective mesenchymal epithelial transition (MET) overexpression (OE) testing of tissue biopsies. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of Mesenchymal Epithelial Transition (MET) protein overexpression (OE) | OE is defined as: positive: >= 25% of tumor cells with 3+ staining intensity, or negative: < 25% of tumor cells with 3+ staining intensity. High overexpression (OE high) is defined as: positive: >= 50% of tumor cells with 3+ staining intensity negative: < 50% of tumor cells with 3+ staining intensity. These are determined by an immunohistochemistry (IHC) performed by the local laboratory. | Up to 15 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non Small Cell Lung Cancer, Telisotuzumab Vedotin, ABBV-399, Cancer
An Evaluation of Patient Reported Outcomes and Clinical Outcomes

Study Overview
=================
Brief Summary
-----------------
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery: Patient reported outcomes (PRO), using the EQ-5D questionnaire Clinical outcomes

Official Title
-----------------
Clinical Protocol REN-007E - Extension Study: An Evaluation of Patient Reported Outcomes and Clinical Outcomes Through 12 Months Post-Cardiac Surgery in Patients Enrolled in Study REN-007

Conditions
-----------------
Post-Operative Complications in Cardiac Surgery

Intervention / Treatment
-----------------
* Drug: RBT-1
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have completed the REN-007 study to be eligible to participate in the Extension Study. Exclusion Criteria: Subjects who did not complete the REN-007 study are not eligible to participate in the Extension Study. Female subjects who become pregnant during the REN-007 study are not eligible to participate in the Extension Study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RBT-1<br>Patients undergoing CABG, valve, or combined CABG/valve surgery | Drug: RBT-1<br>* Intravenous administration<br>|
| Placebo<br>Patients undergoing CABG, valve, or combined CABG/valve surgery | Drug: Placebo<br>* Intravenous administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation | To evaluate patient reported outcomes (PRO) using the EQ-5D questionnaire | 12 Months Post-Cardiac Surgery | 
| Evaluation | The number of subjects with the following clinical outcomes will be reported Clinical Outcomes: Chronic kidney disease (CKD) - new diagnosis Acute kidney injury (AKI) or CKD requiring dialysis Atrial fibrillation - new-onset Death Myocardial infarction (MI) Non-fatal cardiac arrest Readmission to hospital Reoperation for coronary artery bypass graft (CABG) and/or valve dysfunction Stroke | 12 Months Post-Cardiac Surgery |
Comparison of Remimazolam and Propofol Effect on Oxygenation Reservoir During Diagnostic Gastric Endoscopy

Study Overview
=================
Brief Summary
-----------------
Propofol is one of the most commonly used sedative in endoscopic procedures, while its potency to induce respiratory depression may threaten patient safety. Remimazolam is known to less likely induce hemodynamic instability when compared to propofol, yet its favorable effects are not clearly evaluated in endoscopic procedures. Hence, this study aimed to compare hemodynamic effects of remimazolam and propofol, by evaluating oxygen reserve index (ORI) in patients scheduled for diagnostic gastric endoscopy.

Official Title
-----------------
Comparison of Remimazolam and Propofol Effect on Oxygenation Reservoir During Diagnostic Gastric Endoscopy

Conditions
-----------------
Diagnostic Gastric Endoscopy

Intervention / Treatment
-----------------
* Drug: Remimazolam besylate
* Drug: Propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (age 19 80 yrs, ASA Class I III, ECOG 0 1) who are scheduled for elective diagnostic gastric endoscopy Exclusion Criteria: Pregnancy Allergy to remimazolam or propofol Underlying pulmonary diseases or obstructive sleep apnea Hypotension (SBP <80mmHg) or hypoxemia (SpO2 <90%) assessed prior to procedure

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Remimazolam<br>Patient group who receives remimazolam for sedation during endoscopy | Drug: Remimazolam besylate<br>* Patients in this group receives 0.1mg/kg of remimazolam to induce sedation prior to endoscope insertion.<br>|
| Active Comparator: Propofol<br>Patient group who receives propofol for sedation during endoscopy | Drug: Propofol<br>* Patients in this group receives 0.5mg/kg of propofol to induce sedation prior to endoscope insertion.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation | Incidence of Oxygen Reserve Index (ORI) drop to 0.00 will be evaluated after sedative administration, until the end of endoscopic procedure. | Evaluation begins after sedative administration until the end of endoscopic procedure. |
RhabdomYolyse in Intensive caRe

Study Overview
=================
Brief Summary
-----------------
Analysis of the outcome of patients < 18 years old, treated in an intensive care unit for severe rhabdomyolysis, regardless of etiology (renal failure rate, death rate, organ replacement rate)

Official Title
-----------------
RhabdomYolyse in Intensive caRe

Conditions
-----------------
Rhabdomyolysis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CPK > 5000 UI/L Care in Pediatric Intensive Care Unit Age < 18 years old Exclusion Criteria: Parental refusal

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children in intensive care with rhabdomyosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of renal remplacement therapy | Use of renal remplacement therapy in case of severe rhabdomyolysis in children in intensive care unit | 7 days after admission in intensive care unit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rhabdomyolysis, child, Intensive Care